Navigation Links
Warburg Pincus Acquires 5.4% of WuXi PharmaTech's Outstanding Ordinary Shares from United Overseas Bank

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that Warburg Pincus, the global private equity firm, has acquired 5.4% of its outstanding ordinary shares from affiliates of United Overseas Bank.

(Logo: )

At the closing of the transaction on July 2, 2008, affiliates of United Overseas Bank (UOB), one of the early venture investors of WuXi PharmaTech, sold to Warburg Pincus a total of 26,808,496 ordinary shares, equivalent to 3,351,062 American Depositary Shares. A beneficial ownership statement Schedule 13D with respect to this acquisition was filed with the Securities and Exchange Commission.

''I am very delighted that Warburg Pincus has decided to invest in WuXi. As a premier global private equity firm with tremendous experience in the life science industry, Warburg Pincus not only will strengthen our investor base, but more importantly we believe that it will provide strategic and business assistance to us,'' commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

''We are pleased to become a shareholder of WuXi PharmaTech which is a clear leader in the rapidly growing drug and medical device outsourcing industry. WuXi has an impressive track record of growth and a distinguished reputation for customer service,'' said Mr. Stewart Hen, Managing Director of Warburg Pincus based in New York. Added Mr. Dai Feng, Principal of Warburg Pincus based in China, ''With our global expertise in healthcare and our deep understanding of the off-shore operating environment, we hope to assist WuXi in achieving its strategic and financial goals.''

About WuXi PharmaTech

Established in December 2000, WuXi PharmaTech is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in both China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. WuXi's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit .

About Warburg Pincus

Warburg Pincus has been a leading private equity investor since 1971. Since inception, Warburg Pincus has invested more than USD 31 billion in approximately 600 companies in 30 countries and across a range of sectors, including healthcare, financial services, industrial, technology, media and telecommunications, energy, consumer and retail and real estate. The firm has invested USD 6.6 billion in healthcare-related companies around the world. Warburg Pincus has been investing in China since 1995 and is one of the largest private equity investors in the country. The firm has offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, please visit .

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, the anticipated strengthening of our investor base and potential strategic and business assistance to be received. These forward-looking statements are not historical facts but instead represent only our belief regarding future events, which by their nature are inherently uncertain and outside of our control and actual results could differ materially. Our business is subject to numerous risks and this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto and related "Risk Factors", each included in our Annual Report on Form 20-F filed with the Securities and Exchange Commission and available on the Securities and Exchange Commission's website at We do not undertake any obligation to update or revise the forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002


SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Neogen Acquires Product Line From DuPont Animal Health Solutions
3. Decision Resources, Inc. Acquires Manhattan Research
4. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
5. Miltenyi Biotec GmbH Acquires Medic Tools AG
6. Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
7. Touch Bionics acquires LIVINGSKIN
8. Beckman Coulter Acquires Rights to Hepatitis C Virus
9. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... 2015 The 2015 Nobel Prize in Chemistry ... at Dallas. Aziz Sancar , who earned his PhD ... in 1977, is one of three scientists who received the ... repair damaged DNA on a molecular level.  --> Aziz ... from UT Dallas in 1977, is one ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... , Former Majority Leader Richard Gephardt Brings Together ... "Best and Brightest Forum on Medical Innovation" , ... most prominent leaders in biopharmaceuticals, research, medicine and technology gathered ... of medical innovation in New Jersey, and throughout the United ...
... The Burrill Biotech Select Index managed to claw back almost half ... percent mirrored what was also an excellent month for the general ... 4.8 percent in value. The gains held firm in the final ... Thanksgiving holiday shopping and Dubai,s reported debt woes. , Almost all ...
... , CRANBURY, N.J., Dec. 1 Palatin Technologies, ... the U.S. Patent and Trademark Office has issued U.S. ... The claims in the issued patent cover a family ... A (NPRA), including PL-3994, Palatin,s lead heart failure drug ...
Cached Biology Technology:
(Date:9/8/2015)... , Sept. 8, 2015  Affectiva, global ... Emotion as a Service, a new data solution, ... Based on Affectiva,s highly accurate and patented ... analytics capabilities, slated to transform industries such as ... development, retail, customer experience, online education, HR, automotive, ...
(Date:9/2/2015)... , Sept. 2, 2015 Security of ... for enterprises, banks, government organizations, telecommunications, hospitals, as ... keypads were previously being used to prevent unauthorised ... two-factor authentication, wherein individuals could gain access to ... components, such as hardware devices and numeric codes. ...
(Date:9/1/2015)... 2015  Automation and pre-processing are reducing the ... This is the first step toward a future ... unintrusive. An assortment of portal scanners, biometric collection ... will transform the passenger screening process. ... Airport Passenger Screening Market ( ), ...
Breaking Biology News(10 mins):
... of the University of Rochester Chemistry Department received a NYSTAR ... discovery by Huixiang Li, a research associate in his group: ... make sure we're drinking clean water and eating uncontaminated food. ... forensics labs identify criminals, test ponds and pools before children ...
... announced the winner of the 2006 David Horrobin Prize ... The Nurture Assumption and No Two Alike, the article, ... of human hairlessness and skin color" was judged to ... prize, launched in 2004, is awarded annually and named ...
... is an increased risk of fetal heart problems when ... to an abstract presented by Yale School of Medicine ... 9 in San Francisco. , Congenital heart block ... the heart's electrical signaling from the upper to the ...
Cached Biology News:
... Highly efficient delivery of siRNA while ... Electroporate up to 96 samples simultaneously ... from cell harvest to post-electroporation incubation ... , Designed for use with ...
100 adhesive strips....
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: